Daiichi-Sankyo‘s Welchol gets approval for improving glycemic control in adults with Type 2 diabetes.
Novartis – for 11 years in a row – grabs the top spot in the Verispan Managed Care audit.
Roche prevails in its takeover bid for Ventana.
The knives are still out – Wyeth to cut another 10% of workforce?
Vytoringate – Merck and Schering-Plough, taking a beating in the blogosphere and press over Vytorin, try to give an answer to the many questions and charges floating about.
Lipitor has its first – certainly not its last – sales decline.
Stents, stents, and more stents – new study proclaims drug-coated stents safe; bypasses for people with multiple clogged arteries seen as a better option than stents; new coating on stents that “cloaks” them may be more effective than using drug-eluting varieties. (why do I care about progress in the drug-eluting stent marketplace?? – it’s a long story that involves radioactive sources. Ask me some day…)